Skip to main content
. 2021 Mar 13;22(6):2939. doi: 10.3390/ijms22062939

Figure 6.

Figure 6

Intracerebroventricular IND-1233-ASO treatment recovers DA neurotransmission deficits, but not behavioral phenotype, in A30P*A53T*α-Syn transgenic mice. (a) Treatment timeline. A30P*A53T*α-Syn transgenic mice (4 months of age) received randomly vehicle or IND-1233-ASO (100 µg/day) into the lateral ventricle for 28 days using osmotic minipumps. In a group of mice, DA release was examined using intracerebral microdialysis at 3–4 days post-treatment, while behavioral tests were performed in an additional group at 5–6 days post-treatment. All mice were sacrificed on day 10 post-treatment. (b) Microdialysis approach using veratridine and amphetamine agents, as shown in Figure 3, confirmed the normalization of DA neurotransmission in the CPu of A30P*A53T*α-Syn mice treated with IND-1337-ASO (100 μg/day for 28 days) compared with transgenic mice treated with a vehicle. (c,d) No significant differences were detected in the open field test (c) or the dark-light box test (d) between both groups treated with IND-1337-ASO or a vehicle. Data are expressed as the mean ± SEM. Number of mice used in each procedure is indicated in parenthesis. Two-way ANOVA and Tukey’s multiple comparisons test, * p < 0.05, ** p < 0.01 compared to A30P*A53T*α-Syn mice treated with a vehicle.